2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: P

CHICAGO, IL USA (UroToday.com) - Presented by Christophe Massard,1 Carmel Pezaro,2 Dmitri Bobilev,3 Aurelius Omlin,2 Diletta Bianchini,2 David Lorente,2 Laurence Albiges,1 Yohann Loriot,1 Andrea Varga,1 Thi Xuan Quyen Nguyen,4 Karim Fizazi,1 and Johann S. de Bono2 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Complete title: ASCO 2013 - Poster: A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results

asco 2013 massard poster thumb

1 Department of Medical Oncology, SITEP (Service Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif, France; 2Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK; 3Sanofi, Cambridge, MA, USA; 4Sanofi, Chilly-Mazarin, France

 

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage